Catalyst Wire Dossier Catalyst Wire Dossier

everolimus + imatinib mesylate

· Novartis Pharmaceuticals
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for everolimus + imatinib mesylate, covering 2020-09-10 to 2020-09-10. Get the full timeline:

Most recent: Clinical Trial Update: Treatment of Patients With Everolimus and Imatinib Mesylate Who Have Progressive Gastro Intestinal Stromal Tumors (GIST) and Are Resistant to Imatinib Mesylate [Phase 4]

See pricing